Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of APHD-012 in Obese Subjects
NCT05385978Phase 2Active, not recruiting
- Sponsor
- Aphaia Pharma
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of APHD-012 in obesity, sponsored by Aphaia Pharma. Primary endpoint: Changes from Baseline in Percent Weight Change Compared with Placebo at Day 360. Started Nov 2022; status: active, not recruiting.
02
Drugs
APHD-012
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05385978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385978.